TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

CVS Accused Of Years Of Faulty Insulin Refills In $37.8 Million Settlement

Benzinga Logo Benzinga By Vandana Singh
CVS Accused Of Years Of Faulty Insulin Refills In $37.8 Million Settlement

Federal prosecutors alleged CVS Health engaged in improper billing for insulin pen refills between 2010-2020, seeking reimbursement for unnecessary or premature refills across federal healthcare programs. CVS agreed to pay $37.76 million to settle the lawsuit.

Insights
CVS   negative

Company was accused of systematic billing fraud, admitted to improper conduct, and agreed to pay a substantial settlement, indicating significant compliance and ethical issues